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Abstract
Antimetabolites are a class of effective anticancer drugs interfering in essential biochemical
processes. 5-Fluorouracil (5-FU) and its prodrug Capecitabine are widely used in the
treatment of several solid tumors (gastro-intestinal, gynecological, head and neck, breast
carcinomas). Therapy with fluoropyrimidines is associated with a wide range of adverse
effects, including diarrhea, dehydration, abdominal pain, nausea, stomatitis, and hand-foot
syndrome. Among the 5-FU side effects, increasing attention is given to cardiovascular
toxicities induced at different levels and intensities. Since the mechanisms related to 5-FU-
induced cardiotoxicity are still unclear, we examined the effects of 5-FU on primary cell cul-
tures of human cardiomyocytes and endothelial cells, which represent two key components
of the cardiovascular system. We analyzed at the cellular and molecular level 5-FU effects
on cell proliferation, cell cycle, survival and induction of apoptosis, in an experimental cardi-
oncology approach. We observed autophagic features at the ultrastructural and molecular
levels, in particular in 5-FU exposed cardiomyocytes. Reactive oxygen species (ROS) ele-
vation characterized the endothelial response. These responses were prevented by a ROS
scavenger. We found induction of a senescent phenotype on both cell types treated with 5-
FU. In vivo, in a xenograft model of colon cancer, we showed that 5-FU treatment induced
ultrastructural changes in the endothelium of various organs. Taken together, our data sug-
gest that 5-FU can affect, both at the cellular and molecular levels, two key cell types of the
cardiovascular system, potentially explaining some manifestations of 5-FU-induced
cardiovascular toxicity.
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Introduction
The antimetabolite 5-Fluorouracil (5-FU), an analogue of uracil, and its pro-drugs are widely
used antineoplastic agents for the treatment of gastrointestinal cancers, breast, gynecological as
well as head and neck tumors [1]. 5-FU availability for intracellular anabolism mainly depends
on tissue drug catabolism. After administration, 5-FU follows different metabolic destinations:
more than 80% of the dose is inactivated by biotransformation primarily in the liver, approxi-
mately 15–20% is eliminated in the urine and only a small fraction remains available to exert
its anti-tumor action [2].
Capecitabine (N4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine), an orally administered
fluoropyrimidine carbamate 5-FU prodrug, is converted into 5-FU through sequential steps
(S1 Fig.) with preferential activation in tumors because of tissue distribution of key metabolic
enzymes, in particular Thymidine phosphorylase (TP) [3]. 5-FU acts during the S phase of the
cell cycle inhibiting DNA synthesis by restricting availability of thymidylate (S1 Fig.). TP is
also a key enzyme for production of the 5-FU active metabolite [4]. 5-Fluorouracil inhibits thy-
midylate synthetase through its metabolite 5-fluorodeoxyuridine monophosphate (FdUMP).
FdUMP forms a covalent ternary complex with thymidylate synthetase and 5,10-methylene
tetrahydrofolate. Association with folinic acid increases the stability of the complex. 5-FU can
also inhibit RNA synthesis, processing and function [4,5] (S1 Fig.). TP is expressed at low levels
in many tissues throughout the body [6], and at high concentrations in most tumor tissues,
leading to the accumulation of 5-FU in tumors [4,7]. Pharmacokinetic studies performed on
intravenous bolus 5-FU single dose show that maximum plasma concentrations of 5-FU can
reach a millimolar range with a subsequent rapid decline [8–10]. The non-linearity of 5-FU ki-
netics probably reflects the saturation level of metabolic processes or transport at the highest
concentrations of the drug and represents the main reason justifying the difficulty in predicting
the plasma levels or toxicity at high doses [10].
The preferential tumor-accumulation of fluorouracil-based drugs within tumor tissues
favors tolerability, however side effects can occur. Leukopenia, diarrhea, stomatitis, and nausea
manifest frequently in patients treated with 5-FU, while hand-foot syndrome is a typical side
effect of Capecitabine [11]. Cardiac toxicity of fluoropyrimidines, which can be severe and life
threatening, is the second most common cause of chemotherapy-induced cardiotoxicity [12].
Clinical cardiac toxicities associated with 5-FU covers a wide range of manifestations: coronary
vasospasms and subsequent calcium antagonist non-responding angina, myocardial infarction,
ischemia, dysrhythmia, cardiomyopathy, tako-tsubo cardiomyopathy, sinoatrial and atrioven-
tricular nodal dysfunction, QT prolongation with torsades de pointes ventricular tachycardia,
cardiac arrest and sudden death have been reported in the literature [12–21]. Heart failure is
reported in 3.5% of patients, often during the first cycle of chemotherapy [22] and specific side
effects occur when 5-FU is administered either as a single agent or in combination with inter-
mediate-dose folinic acid [23]. Recent meta-analyses for fluoropyrimidine cardiotoxicity not
only indicates incidence ranging from 0–20% for 5-FU and 3–35% for Capecitabine [20,21],
but also highlighted an increased risk of toxicity during administration of higher doses of 5-FU
as well as of concomitant cisplatin treatment, or of continuous infusion as compared to bolus
administration. Subclinical cardiac toxicity may be much higher. In a prospective study, 29% of
patients receiving 5-FU had evidence of cardiac toxicity (N-terminal probrain natriuretic pep-
tide elevation, a marker of left ventricular dysfunction) [22]. Difference in incidence of cardio-
toxicity between studies could be a reflection of different risk profiles [20]. In a multivariate
analysis patients with preexisting cardiovascular disease have a relative risk of 8 for cardiotoxi-
city compared to patients without cardiac disease [22]. A high rate of recurrence of cardiac tox-
icity after rechallenge is reported, varying from 20% to 100% [24,25]. A literature review
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indicated an overall death rate of 0.32% for first administration, whereas re-exposure of those
subjects who previously had cardiac toxicity led to 13% death rate, 40-fold higher [26].
Some 5-FU metabolites are also associated with toxicity, in particular alpha-fluoro-beta-
alanine has been associated with neuro- and cardiotoxicity [27]. Thymidine phosphorylase
(TP) is a key enzyme involved in conversion of Capecitabine to 5-FU and 5-FU to its active me-
tabolites. TP was also found to be an angiogenic factor (known as platelet-derived endothelial
cell growth factor) [28,29]. TP expression is up-regulated in atherosclerotic plaques [30] and
during myocardial infarction [31], potentially contributing to the higher prevalence of cardio-
toxicity in patients with previous cardiovascular disease or 5-FU induced damage.
Follow up studies have shown that a key point to take into consideration is that the time of
cardiotoxicity clinical manifestation is widely variable, eventually being immediate or at late
onset, years or decades after treatment [16–18,32,33] and more importantly this risk is individ-
ual [16–18,32]. The incidence and severity of cardiac events depend on the type of drugs used,
the dose and the schedule employed as well as on patient age, presence of coexisting cardiac
diseases or previous mediastinal irradiation [16–18,32]. Acute cardiac toxicity often can be pre-
vented by interrupting treatment when the patient is close to the maximum cumulative dose,
while long-term effects are difficult to predict since they become apparent long after chemo-
therapy, often as a result of a stressful event, surgery, pregnancy or changes in lifestyle [34,35].
In terms of cardiotoxicity, the most well studied anti-tumor agents are anthracyclines, tras-
tuzumab, and their combination [17,36,37]. Less is known about the mechanisms of fluoropyr-
imidine induced cardiotoxicity. Among the numerous possible effects [12,21] current
hypotheses involve: 1) An imbalance between anabolic and catabolic processes during bio-
transformation, leading to the considerable inter-individual variability [1]. 2) A direct 5-FU
mediated damage to the vascular endothelium, followed by thrombosis, characterized by the
release of vasoactive substances and vasospams or the alteration of the antioxidant defense ca-
pacities in myocardial tissues, due to the exhausted activity of the cardiac enzymes superoxide
dismutase and glutathione peroxidase [13,14]. In few cases coronary artery vasospasm and
vasoconstriction has been visualized during coronary angiography immediately after 5-FU in-
jection [17,36,37], while cardiotoxicity may occur at the end of infusion or hours to days later
[38].
In order to develop effective cardiotoxicity prevention strategies, a deeper and conclusive
knowledge of the causes of these toxicities is needed. The effects of fluoropyrimidines have
been investigated on several cell types (tumor and normal cells) including smooth muscle
cells [39], and on numerous animal models, but the effects of 5-FU on human endothelial cells
and cardiomyocytes has, to our knowledge, not been previously investigated. Given the broad
range of cardiac toxicities associated with 5-FU [12,21], these studies are needed to help
understand the effects on the cardiovascular system [38]. To shed light on some of the mecha-
nisms of 5-FU cardiotoxocity, here we examined the effects of 5-FU on endothelial cells and
cardiomyocytes in vitro and in a colorectal cancer xenograft model, analyzing both at cellular
and molecular levels the mechanisms involved in cardio-vascular toxicity associated with 5-
FU treatment.
Materials and Methods
Cells and reagents
Human umbilical vein endothelial cells (HUVECs) (Promocell, Heidelberg, Germany) were
grown on 1% gelatin-coated tissue culture plates in M199 growth medium (Sigma-Aldrich, St
Louis, MO, USA), supplemented with heat inactivated 10% FBS (Sigma-Aldrich), 2 mM gluta-
mine (Gibco-Life Technologies, Thermo Fisher Scientific, Waltham, MA, USA), 100 μg/ml
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heparin sodium salt (Sigma-Aldrich), 10 μg/ml hydrocortisone (Sigma-Aldrich), 10 ng/ml en-
dothelial growth factor (EGF), 10 ng/ml acid and basic fibroblast growth factor (aFGF, bFGF)
(Peprotech, Rocky Hill, NJ, USA). Human cardiac myocytes (HCMs, Promocell) were grown
in Supplemented Myocyte Growth Medium (Promocell). Primary cell cultures were maintained
at 37° C and 5% CO2 and were used in all in vitro experiments between passages 3 and 8.
Human colorectal cancer (CRC) cell lines HCT-116 and HT29 (both from ATCC) were
cultured on McCoy medium (Gibco-Life Technologies), murine CT26 CRC cells (ATCC) were
cultured in RMPI1640 medium (Gibco-Life Technologies), all supplemented with heat inacti-
vated 10% FBS (Sigma-Aldrich), 2 mM glutamine (Gibco-Life Technologies) and 1% penicil-
lin/streptomycin (Invitrogen, Life Technologies).
5-Fluorouracil (5-FU), 1-(4,5-dimethylthiazol-2-yl)-3,5-diphenylformazan (MTT), the
Toxicology Assay Kit (TOX7), Propidium Iodide (PI), the Senescence Cells Histochemical
Staining Kit, 2',7'-dichlorodihydrofluorescein-diacetate (DCFH-DA), N-acetyl-L-cysteine
(NAC), Acridine Orange (AO) and Vincristine were purchased from Sigma-Aldrich. The FITC
BrdU flow kit, Matrigel, Annexin V and 7AAD were purchased from BD Biosciences (San Jose,
CA, USA).
Cell proliferation assay
HUVECs were seeded on 1% gelatin coated tissue culture plates at 2x103 cell/well in 96-well
plate. HCMs were plated at the same density in their specific growth medium. HCT-116 and
CT26 were seeded at 1x103 cells/well, HT29 at 3x103 cells/well, in 96-well plates. After a 24
hour incubation in their respective media to allow for cell attachment, the medium was
changed and the cells were treated with serial 10-fold dilutions (10 nM to 1 mM) of 5-FU
dissolved in DMSO. As negative controls, growth medium with DMSO alone were used, 0.1%
saponin was the positive control. All conditions were incubated for up to 96 hours and 6–8
replicates were done for each time-point. The MTT reagent was added to a final concentration
of 0.5 mg/ml to each well. After 5 hours incubation at 37°C, medium was removed, formazan
crystals were dissolved with 100 μl of DMSO and absorbance read at 570 nm in a micro-plate
reader. Non-viable cells are unable to reduce the MTT dye, giving an indirect measure of 5-FU
effects on cell number. The concentration of drug that reduced cell proliferation by 50% (EC50)
was calculated by non-linear regression fit using GraphPad Prism.
Detection of apoptosis by flow-cytometry
The proportion of apoptotic cells was detected by the Annexin V / 7AAD staining. HUVE or
HCM cells were plated at a density of 5x104 cells/well on 6-well plates and grown overnight. The
subsequent day the cells were treated with increasing 5-FU concentrations. Controls received
DMSO (negative) or Vincristine (positive). Each treatment was in triplicate and three different
experiments were performed. After 96 hours, cells were harvested, counted, transferred into flow
tubes, pelletted, resuspended in 100 μl of fresh 1X Annexin binding buffer (0.01 MHEPES pH
7.4; 0.14 M NaCl; 2.5 mMCaCl2) plus Annexin V fluorescein isothiocyanate (FITC) and 7AAD
peridinin-chlorophyll protein (PerCP). After staining, samples were analyzed by flow cytometry
within 1 hour using a FACSCanto (BD). Annexin V+/7AAD± were considered as apoptotic cells.
The proportion of apoptotic cells was expressed as a percentage of the total cell number acquired,
excluding debris, and analyzed using the BD FACSDiva and FlowJo software.
Cell cycle analysis
Assessment of cell proliferation was evaluated both with classic PI staining and through
direct measurement of DNA synthesis using incorporation of the nucleoside analog
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bromodeoxyuridine (BrdU). For PI staining, cells were plated on 6-well plates, grown over-
night, treated in triplicate with the same concentrations and controls as above. Treatments
were continued up to 96 hours and each well was collected singularly into flow tubes. Cells
were fixed and permeabilized with 70% cold ethanol for at least 1 hour at-20°C, then washed
twice with cold Phosphate Buffer Solution 1X and stained for 40 minutes at 37°C with PI solution
(50 μg/ml PI in H2O, 0.1% Triton-X100, 0.1% trisodium citrate dehydrate, 6.25 μg/ml RNase A).
Cells were analyzed by flow cytometry within 3 hours using a FACSCanto machine (BD) and
analyzed with BD FACSDiva Software 6.0.
For BrdU staining, asynchronized log-phase growing cells (40% confluent) were treated
96 hours with 5-FU (100 nM—1 mM) or with DMSO in complete medium. As a positive con-
trol 50 nM Vincristine, known inhibitor of cell cycle, was added as a positive control 48 hours
before the end of treatment. BrdU (10 μM) was added 12 hours before the end of the experi-
ment, thus only cells still capable of replication following 5-FU treatment are able to incorpo-
rate BrdU. BrdU incorporation was measured using an anti-BrdU FITC-conjugated antibody
and detected by flow cytometry along with 7ADD staining for total DNA.
LDH assay
Lactate dehydrogenase (LDH) is an intracellular enzyme that is released in the tissue culture
supernatant when cell membranes are damaged, and it is also a marker for cardiac myocyte in-
jury [40]. HUVECs and HCMs were plated on 96 well plates, as previously seen and exposed
for 96 hours to varying concentrations of 5-FU, DMSO alone or 0.1% saponin (negative and
positive controls, respectively). Lactate dehydrogenase release was detected using the TOX7
(Sigma-Aldrich) colorimetric assay according to the manufacture's instructions.
Ultrastructural analysis
For ultrastructural analysis, HUVE and HCM cells were treated with 1 mM 5-FU for 72 or
96 hours. Growth media alone and containing DMSO were used as controls. Cells were fixed in
a mixture of 2% paraformaldehyde and 2% glutaraldehyde, post-fixed in 1% osmium tetroxide,
and embedded in Epon-Araldite (Sigma-Aldrich). After counterstaining with uranyl acetate
and lead citrate, thin sections were examined with a Morgagni electron microscope (Philips,
Eindhowen, NL) at 7100X magnification.
Reactive Oxygen Species (ROS) detection
ROS detection protocol was adjusted from that described previously [41]. HUVECs and HCMs
were plated on 6-well plates, at 5x104 cells/well. The following day, cells were treated with serial
dilutions of 5-FU (10 nM—1 mM). DMSO and N-(4-hydroxyphenyl)retinamide (4HPR,
Sigma-Aldrich) were used as controls. After 96 hours cells were harvested, centrifuged and
washed in PBS and loaded with 50 μM 2',7'-dichlorofluorescein-diacetate (DCFH-DA) for
10 minutes at 37°C. Fluorescence was detected with a FACSCanto cytometer (BD) on the FL1
channel and analyzed with FACSDiva 6.0 software. In some experiments the ROS scavenger
NAC (10 mM) was added concomitant with 5-FU treatments.
Detection of Acidic Vesicular Organelles (AVOs)
Cells undergoing autophagy develop double-membrane, acidic vesicular organelles (autopha-
gosomes, AVOs), which can be detected by specific dyes, in particular acridine-orange (AO).
AVOs were quantified by flow cytometry after staining of cells with AO. Cells were plated and
treated as above in 6-well plates for 96 hours, then harvested, collected in flow tubes and
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washed in PBS. The cell suspension was stained with AO (5 μg/ml) for 15 min at room temper-
ature, then washed twice in PBS, resuspended in PBS and analyzed by flow cytometry. Fluores-
cence was read on the FL2 channel (PE) on a FACSCanto cytometer (BD) and analyzed with
FACSDiva 6.0 software. The AO bright red fluorescence intensity is proportional to the degree
of acidity and correlate with AVOs formation. In some experiments the ROS scavenger NAC
(10 mM) was added concomitant with 5-FU treatments.
Immunocytochemistry for LC3 localization
Endothelial cells and cardiomyocytes were separately plated at 5 × 103 onto 8-well chamber
slides (Nunc, Thermo Fisher Scientific) and treated with 5-FU as above, washed with PBS and
fixed with 4% paraformaldehyde at 37°C for 30 min. Cells incubated with DMSO and 10 μM
Cloroquine served as negative and positive controls. Cells were permeabilized with 0.5% Triton
X-100 for 8 hours at 4° C and blocked with 0.2% bovine serum albumin (BSA) for 1 hour at
room temperature. The cells were labeled with polyclonal rabbit anti-human LC3 (Cell Signal-
ing Technology, Beverly, MA, USA) overnight at 4°C, and with Alexa Fluor 555 goat anti-
rabbit secondary antibody (Invitrogen, Thermo Fisher Scientific) for 2 hours at room tempera-
ture in the dark. Images were acquired at 63X magnification with immersion oil under a Zeiss
(Zeiss, Jena, Germany) fluorescent microscope.
Western Blotting Analysis
Western blotting was performed with a SDS-PAGE Electrophoresis System. Cells were treated
with 5-FU for 96 hours, then collected by plate scraping on ice. Total lysates were prepared
using Cell Lysis Buffer (Cell Signaling Technology) and protein concentrations evaluated by
the DC Protein Assay (Bio-Rad, Hercules, CA, USA). Equal amounts of proteins for each sam-
ple were resuspended in reduced sample buffer, resolved on a 12% SDS-PAGE and blotted
onto polyvinylidene fluoride (PVDF) membranes (Amersham Biosciences, Otelfingen, Swit-
zerland). Following non-specific blockage with 5% non-fat milk powder (w/v) in Tris-buffered
saline (10 mM Tris–HCl, pH 7.5, 100 mMNaCl, 0.1% Tween-20) for 1 hour at room tempera-
ture, membranes were probed with polyclonal primary antibody rabbit anti-human LC3A/B
antigen (Cell Signaling). The antibody was diluted in 5% bovine serum albumin-0.1% Tween-
Tris-buffered saline according to the manufacturer's instructions. Horseradish peroxidase-
conjugated secondary antibodies were then added and the resulting signal detected through
autoradiography using chemiluminescence (ECL, Amersham Biosciences). Rabbit anti-human
anti-tubulin antibody (Cell Signaling), used according to the manufacturer instructions, served
as a reference for normalization.
Analysis of senescence induction
HUVECs or HCMs were seeded at 5x103 cells/chamber in an 8-well chamber slide and treated
with 5-FU up to 72 hours. Cells were then processed using a Senescence Cells Histochemical
Staining kit (Sigma-Aldrich) as indicated. Briefly: media was removed and cells were washed in
PBS, fixed and stained with a β-galactosidase reagent. Chamber slides were incubated over
night at 37°C without CO2 and then observed in bright field and fluorescence after mounting
with DAPI containing Vectashield Mounting Medium (Vector Laboratories, Burlingame, CA,
USA). The ratio between the β-galactosidase positive blue-stained cells (bright field) and total
amount of DAPI stained nuclei (fluorescence) was calculated per each observed field and the
results reported as mean of percentages of senescent cells per treatment.
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Evaluation of 5-FU cardiovascular toxicity in vivo
CT26 murine colon cancer cells (1x106) were suspended in 100 μl of matrigel (BD) and subcu-
taneously injected into the flanks of 6–8 week old BALB/c mice (Charles River Laboratories,
Calco-Lecco, Italy). The animals were treated by intraperitoneal injection with either 10 mg/Kg
5-FU every 48 hours or 1 mg/Kg 5-FU every day, or vehicle alone, starting when tumors were
palpable. Tumor dimensions were measured by a caliper in two dimensions, the tumor volume
(mm3) was calculated using the formula width2 × length/2. After 20 days, mice were sacrificed,
organs and tumors were collected, fixed overnight in 4% paraformalaldeyde and stored in 70%
ethanol. For transmission electron microscopy, tissues were then post-fixed in 1% osmium te-
troxide, and embedded in Epon-Araldite (Sigma-Aldrich), and processed for electron micros-
copy as above. For light microscopy, tissues were embedded in paraffin and sections stained
with hematoxylin and eosin using standard protocols. All animals were housed in a conven-
tional animal facility with 12 hours light/dark cycles and fed ad libitum. The use of animals was
in accordance with the Italian and European Community guidelines (D.L. 2711/92 No.116; 86/
609/EEC Directive) and approved by the institutional ethics committee. Groups of 4–8 mice
were used for each treatment.
Statistical analysis
Statistical analyses were performed using Prism software (GraphPad), two-tailed t-tests for
comparison of two data sets and one-way or two-way ANOVA for multiple data sets were ap-
plied, P<0.05 was considered statistically significant. Means ± SEM of experiments performed
in triplicate or quadruplicate are shown.
Results
Effects of 5-FU on endothelial cells and cardiomyocyte cell growth and
survival
We initially evaluated the effects of 5-FU on HCM (Fig. 1A) and HUVE (Fig. 1B) cell prolifera-
tion using a standard MTT assay. Inhibition of endothelial cell growth became statistically
significant at 10 μM or higher concentrations of 5-FU already after 24 h, and was maintained
throughout the entire time-course. Doses lower than 10 μM did not show cytostatic effects. A
similar response to 5-FU treatment was found for HCM: 10 μM or higher concentrations ex-
erted cytostatic effects, lower concentrations of 5-FU did not influence cell proliferation. We
compared the effects on vascular cells to the therapeutic outcomes exerted on colon cancer
cells. Comparison of 5-FU efficacy on colon cancer cell lines (HCT116, HT29; Fig. 1C, D)
confirmed a response, with half maximal effective concentration (EC50) of 13.72 μM for
HCT116 and 106.8 μM for HT29 cells (Fig. 1E). Side effects on vascular cells occurred at EC50
of 3.832 μM for HUVECs and 4.866 μM for HCMs. Cellular replication rates varied widely
between cardiomyocytes, endothelial and tumor cells (S2 Fig.).
Initial cell cycle analysis using PI staining indicated a trend toward an increase in apoptotic
cells and a decrease in replicating (S phase) endothelial cells with 5-FU treatments greater than
1 μM (S3A Fig.). We further investigated the 5-FU cytostatic/cytotoxic effects using the Lactic
Dehydrogenase (LDH) release assay, which measures loss of membrane integrity through de-
tection of LDH enzyme activity in the culture medium. 5-FU concentrations greater than 1 μM
significantly compromised cell membrane integrity for both cardiomyocytes and endothelial
cells (Fig. 2A, B). We examined in depth the ability of 5-FU to induce apoptosis using Annexin
V and 7AAD staining (Fig. 2C, D). After a prolonged (96 hour) treatment with 5-FU, both cell
types showed 5-FU induced cell death (Annexin V+/7AAD±) (S4 Fig.) with percentage of
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Figure 1. Cytostatic/cytotoxic effects of 5-FU on cardiomyocytes and endothelial cells. The cytostatic effect of 5-FU on HCMs (A) was not marked but
statistically significant starting at 48 hours and from 10 μM 5-FU. The inhibitory effect of 5-FU was significant in endothelial cells (B) already after 24 hours at
the intermediate concentration of 10 μM. The inhibition of cell viability was maintained up to 96 hours. Drug efficacy was also tested on the HT29 and
HCT116 colorectal cancer cell lines (C, D). Mean ± S.E.M. of four different experiments for each cell type is shown. (E) MTT data at 72 hours were used to
calculate the EC50 values using the non-linear regression function of GraphPad Prism. 5-FU concentrations are reported in μM on a Log(10) scale, DMSO:
0.2% DMSO (vehicle) negative control, 0.1% saponin, positive control.
doi:10.1371/journal.pone.0115686.g001
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apoptosis induced in cardiomyocytes and endothelial cells statistically significant (P<0.05) for
concentrations of 10 μM, 100 μM and 1 mM (Fig. 2C, D).
5-FU effects on the cell cycle were further examined using an assay where cellular DNA
content was directly labeled with 7AAD while proliferative capacity following 84 hours of treat-
ment with 5-FU was assessed by a 12 hours incorporation of BrdU (Fig. 2 E, F). Two gates were
set on the BrdU/7AAD cytograms (S3B Fig.) according to BrdU content: BrdU-unlabeled
(BrdU-) cells in the bottom gate represent cells in G1 and G2/M phases, while BrdU-labelled
cells (BrdU+) in the upper gate represent replicating cells in S phase. Staining of HCMs re-
vealed a certain degree of replicating capability in the negative control and at the lower concen-
trations of drug (100 nM and 1 μM, light grey bars, Fig. 2E). Treatment with 5-FU revealed
high sensitivity with complete absence of cells in the BrdU+ fraction at doses of 1 μM or higher
(Fig. 2E). Similarly, endothelial cells showed a dose dependent accumulation of BrdU- cells in
G1 and G2/M in the presence of 5-FU (Fig. 2F). Cells in the BrdU+ fraction decreased from
42.6% in the negative control to 36.5% at 100 nM, 31.7% at 1 μM and 4.4% at 10 μM and were
undetectable at 100 μM and at 1000 μM 5-FU.
5-FU induces autophagy of endothelial cells and cardiomyocytes
Transmission electron microscopy analysis of 5-FU treated endothelial cells and cardiomyo-
cytes showed clear signs of autophagy (Fig. 3). Both HCM and endothelial cells treated with
1 mM 5-FU for 72 and 96 hours showed signs of distress with rupture of mitochondrial
cristae, dilatation of the cisternae of the endoplasmic reticulum, and in cardiomyocytes, nu-
merous autophagic vacuoles as compared to controls (growth medium and growth medium
with DMSO vehicle). To further analyze induction of autophagy, acidic vesicular organelles
(AVOs), which consist of autophagosomes and autolysosomes, were quantified by flow cytom-
etry after cell staining with AO, a weak base that accumulates in acidic areas (Fig. 4). A time-
and dose-dependent, statistically significant accumulation of AVOs in cardiomyocytes during
5-FU treatment was found (Fig. 4A). In contrast, endothelial cells generally did not show an
increase in AVOs with 5-FU treatment (Fig. 4B).
To confirm the establishment of an autophagic process in cells treated with 5-FU, we stained
HCMs and HUVE cells with an anti-LC3 antibody (Fig. 5), a major constituent of the autopha-
gosome. This double membrane structure sequesters the target organelle/protein and then
fuses with endo/lysosomes where the contents—and LC3—are degraded. Confirming the re-
sults obtained with AO, LC3 staining was detected in 5-FU-treated HCMs (Fig. 5A) at all con-
centrations analyzed (1 μM to 1000 μM). In endothelial cells (Fig. 5B) only a light, diffused
presence of the cytoplasmic form of LC3 was detected, LC3-associated punctae were only ob-
served at the highest dose (1000 μM). The positive control (10 μMCloroquine) clearly showed
accumulation of LC3 punctae both in HUVECs and HCMs. These data were also confirmed
using western blot analysis for LC3 expression in HCMs (Fig. 5C).
5-FU induces reactive oxygen species generation
Reactive oxygen species (ROS) are often released by cells in response to chemotherapeutic
drugs and are cytotoxic [42]. We investigated intracellular ROS production in HCMs and en-
dothelial cells using DCFH-DA staining, a cell penetrating dye that becomes fluorescent after
reacting with ROS. We observed a dose- and time-dependent generation of ROS in both cell
types (Fig. 6). In basal conditions both cell types showed a comparable low level of ROS. When
treated with 5-FU, HUVE and HCM cells showed a concentration dependent, statistically sig-
nificant elevated ROS production, reaching peaks 10 to 100 μM 5-FU at all time points as-
sessed. There was a statistically significant increase in ROS production (Fig. 6) at 5-FU doses
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Figure 2. Effects of 5-FU on HCMs and HUVECs integrity and cycling ability.Membrane damage was calculated as the ratio between released LDH and
total LDH. The effect of 5-FU on LDH release was statistically significant at 5-FU concentrations higher that 10 μM, less marked on cardiomyocytes
(*P<0.05; **P<0.001) (A) with respect to HUVECs (****P<0.0001) (B). Mean ± S.E.M. of three different experiments for each cell type is shown. After 96
hours of 5-FU treatment cells were collected and stained with Annexin-V/7AAD to determine induction of apoptosis. Cumulative graphs of three independent
experiments showing Annexin V+/7AAD± cells are shown. Higher concentrations induced statistically significant amount of apoptotic cells as compared to
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below the EC50 (Fig. 1) for both HCM and HUVE cells. ROS production was confirmed using
the ROS scavenger NAC [43]. Contemporary treatment with 5-FU and NAC significantly re-
duced ROS levels for both HCM and HUVEC (Fig. 7A-D). We then examined the effect of
NAC on AVOs formation as a surrogate for autophagy. NAC significantly inhibited AVOs for-
mation in cardiomyocytes (Fig. 7E). Since the HUVEC response to 5-FU did not involve AVOs
(Fig. 4B), NAC was also ineffective at modulating AVOs levels (Fig. 7F). Influence of NAC and
5-FU co-treatment was also evaluated on the HCT116 CRC cell line, where NAC enhanced the
cytotoxicity of 5-FU toward the tumor cells (data not shown).
Induction of senescence by 5-FU
ROS production is associated with senescence induction, in particular in endothelial cells
[44,45]. Replicative senescence or stress-induced premature senescence has been described in
vitro [46]. This latter type of senescence process has been associated with drugs acting on
DNA, including 5-FU [47–49]. Senescent endothelial cells are characterized by increased activ-
ity of senescence-associated β-galactosidase (β-GAL) and the senescence-associated secretory
phenotype associated with atherosclerosis and vascular dysfunction [46,50]. Previous studies
have suggested that physiologically senescent cells also loose their angiogenic potential [51].
Given the generation of ROS by 5-FU, we investigated senescence induction using β-GAL ac-
tivity, which is readily detectable in senescent cells, yet undetectable in quiescent, immortal or
tumor cells. After 72 hours of treatment with 5-FU, the numbers of total and senescent cells
per field were counted and results reported as percentage of senescent cells per concentration.
Both cell types showed a dose dependent statistically significant increase in the percentage of
senescent cells compared to control (Fig. 8). HUVE cells showed significantly increased average
percentages of senescent cells at the higher drug concentrations, from 47% in untreated control
to 66%, 69% and 63% in 10, 100 and1000 μM, respectively. This was accompanied by an abso-
lute reduction in total HUVE cell number with a relative increase in senescent cells (visible in
bright field pictures, Fig. 8C). In HCM, the basal level of senescent cells was higher than endo-
thelial cells (53%, physiologically expected) and the greater sensitivity to β-GAL staining is
evident starting at low concentrations of 5-FU. The number of β-GAL stained cells (Fig. 8B)
was significantly increased for all the concentrations from 0.1 to 1000 μM except for the 10 μM
point (63%, P<0.005; 64%, P<0.01; 62%, not significant; 58%, P<0.05; 66%, P<0.005 respec-
tively, as compared to control). Our data showed that induction of senescence could be consid-
ered an additional mechanism by which 5-FU impairs cells function, leading to vascular
collapse or vasospasm associated with 5-FU cardiac toxicity.
Cardiovascular toxic effects of 5-FU in vivo
We initially evaluated the sensitivity murine colon adenocarcinoma cell line CT26 to 5-FU
in vitro using the MTT assay (Fig. 9A inset). In vivo, treatment with 5-FU given every day
(1 mg/kg) or every two days (10 mg/kg) showed a significant inhibition of tumor growth
(Fig. 9A) and of tumor weight (Fig. 9B). Hematoxylin/eosin staining did not show any evident
alterations of the cardiac or renal tissues (Fig. 9C). In heart tissues only minor alterations of
negative control both in HCM (* P<0.05) (C) and HUVEC (**P<0.01; ***P<0.005) (D). Impairment of proliferative capacity was assessed using BrdU
incorporation after 84 hours of treatment with 5-FU. BrdU-unlabeled cells (BrdU-) represent cells in G1 and G2/M phases, BrdU-labeled cells (BrdU+)
represent replicating cells in S phase. Staining of HCMs (E) revealed a certain degree of replicating capability in the negative control and at the lower
concentrations of 5-FU, with complete absence of cells in the BrdU+ fraction in doses of 10 μM or more. Endothelial cells (F) display a dose dependent
accumulation of BrdU- cells in G0 in the presence of 5-FU. Mean ± S.E.M. of three different experiments for each cell type is shown. Negative controls (Ctrl-)
consisted of cells treated with vehicle alone (0.2% DMSO), positive controls (Ctrl+) were cells treated with 0.1% saponin.
doi:10.1371/journal.pone.0115686.g002
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Figure 3. Ultrastructural analysis by electron microscopy. HCMs in culture without any treatment (A 1, 4) or treated with DMSO (A 2, 5) showed only very
mild signs of distress. HCMs treated with 1 mM 5-FU for 72 and 96 hours (A 3, 6) showed signs of suffering including rupture of the mitochondrial christae,
dilatation of reticulum cysternae and autophagic vacuoles. HUVEC in culture without any treatment (B 1, 4) or treated with DMSO (B 2, 5) did not show any
signs of mitochondrial rupture. HUVEC treated with 1 mM 5-FU for both 72 and 96 hours (B 3, 6) showed several signs of injury (rupture of mitochondrial
christae and dilatation of reticulum cysternae).
doi:10.1371/journal.pone.0115686.g003
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endothelial nuclei were detected in the 10 mg/kg treatment group which might be a sign of en-
dothelial cell stress. The cardiomyocytes appeared unaffected. Transmission electron microsco-
py indicated cytoplasmic vacuolization and membrane breakage of endothelial cells in renal
tissues (Fig. 9D), an organ often involved in early symptoms of cardiovascular toxicity due to
anticancer drugs [52,53].
Discussion
There is increasing awareness that toxicity to the cardiovascular (CV) system limits treatment
efficacy and affects the quality of life of the cancer survivor [16–18,32,35]. Anthracyclines are
known to cause CV toxicity, in particular in combination with trastuzumab [16–18,32], which
by itself has some degree of cardiotoxicity [16–18,32,54]. Reports of cardiac toxicities of fluoro-
pyrimidines (5-FU and its prodrugs) are increasing although a conclusive explanation of these
effects is still lacking. To shed additional light on this, we investigated the effects of 5-FU on
human endothelial cells and cardiomyocytes, key components of the CV system both of which
are affected by fluoropyrimidine chemotherapy. There are several limitations to this study, in-
cluding the use of human in vitromodels and relatively “young”murine in vivomodels. How-
ever, we feel these data do reflect some potential clinical scenarios in patients treated with 5-FU
and its pro-drugs.
The concentrations of 5-FU used here mimic those of several clinical studies [24,25], bolus
intravenous administration results in plasma peaks up to the millimolar range with a rapid de-
cline, while with continuous infusions of 5-FU were in the 1.4–6.7 μM range. Infusion with
Capecitabine resulted in therapeutic dosing between 3.46 and 6.53 μM [55]. Further, the EC50
of effects on cardiomyocytes and endothelial cells was similar to that of CRC cell lines in vitro.
5-FU affected that proliferative capacity of both cardiac myocytes and endothelial cells, in
agreement with previous studies [56–59].
A decrease in the cycling rate might be a mechanism of tumor 5-FU escape [60], thus it
could be hypothesized that slow replicating potential could be a protection against the effects
of 5-FU on normal cells. However, our data suggest that this is not the case, where we observed
a decrease in endothelial cells in S and G2/M, while in cardiomyocytes we found a slight
Figure 4. Acidic Vesicular Organelles (AVOs) formation in HCM after 5-FU treatment. AVOs formation is associated with the establishment of an
autophagic process. Prolonged treatment with 5-FU significantly increased AVOs accumulation (*P<0.05; **P<0.01; ***P<0.005; ****P<0.0001) in HCM
(A) as compared to control. Both 48 as well as 96 hours treatment of HUVEC (B) did not significantly influence the amount of acidic compartment staining
over time. Mean ± S.E.M. of four different experiments per cell types are shown.
doi:10.1371/journal.pone.0115686.g004
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Figure 5. LC-3 expression as autophagic marker induced by 5-FU treatment. Staining with anti-LC3 showed punctae formation associated with the
induction of the autophagic process. HCM (A) at all concentrations evaluated showed presence of LC-3 positive vesicles, while in HUVEC (B) the presence
of these structures were not detectable unless using the highest 5-FU concentration. Cloroquine used as a positive control (Ctrl+) clearly induced vesicle
formation. (C) Western blot analyses confirmed LC3 expression and increase on HCMs at the higher concentration of the drug.
doi:10.1371/journal.pone.0115686.g005
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Figure 6. Induction of reactive oxygen species by 5-FU. DCFH-DA stained cells revealed an increased ROS production after 48, 72 and 96 hours of
treatment with increasing concentrations of 5-FU. The percentage of cells positive for ROS production was statistically significant at several concentrations
examined for both cell types (A, B). *P<0.05; **P<0.01; ***P<0.005. 4-HPR and 0.2% DMSO (vehicle) were used as positive and negative controls.
Mean ± S.E.M. of four different experiments for each cell type is shown.
doi:10.1371/journal.pone.0115686.g006
5-Fluorouracil Effects on Endothelial Cells and Cardiomyocytes
PLOS ONE | DOI:10.1371/journal.pone.0115686 February 11, 2015 15 / 25
Figure 7. Effects of a ROS scavenger on ROS and AVOs formation.HCM and HUVE cells treated with 5-FU at the indicated concentrations together with
the ROS scavenger NAC (10 mM) resulted in a reduction of ROS production. Both relative ROS as percentage of negative control (A, B) and representative
histograms of flow cytometric data (C, D) are shown; light grey histograms 10 μM 5-FU, dark grey histograms 100 μM 5-FU, black histograms 1000 μM 5-FU;
grey shaded histograms = negative control (Ctrl-); solid lines = 5-FU; dotted lines = 5-FU+NAC. NAC also reduced formation of AVOs in HCM (E), suggesting
that ROS is also involved in the autophagic response in these cells. Since endothelial cells did not show induction of AVOs, NAC has little effect on AVO
production in these cells (F). *P<0.05; **P<0.01. Mean ± S.E.M. of three different experiments for each cell type is shown.
doi:10.1371/journal.pone.0115686.g007
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Figure 8. Senescence induction by 5-FU. After 72 hours of treatment with 5-FU (shown in μM), both cell
types display a dose-dependent increase in the percentage of senescent cells. Representative images of
β-GAL-stained blue-senescent cells are shown for 5-FU or DMSO treated HCMs (A) and endothelial cells
(C). The ratio between the β-galactosidase positive blue-stained cells and total nuclei was calculated for each
observed field and the results reported as mean of percentages of senescent cells per treatment (B, D). Five
fields per conditions were observed; mean ± S.E.M. of three different experiments for each cell type is shown.
(*P<0.05; **P<0.01; ***P<0.005; ****P<0.0001).
doi:10.1371/journal.pone.0115686.g008
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increase in G2/M phase, and a complete absence of replicating cells at higher 5-FU concentra-
tions. The dissimilar behavior (e.g. accumulation in diverse phases of cell cycle) of different cell
types in response to 5-FU is not surprising, tumor cells of various histotypes showed different
cell cycle distribution after 5-FU treatment [61].
Although having a limited replicative potential, cardiomyocytes were quite sensitive to
5-FU. Consistent with recent publications investigating primary and immortalized rat cardio-
myocyte cell lines [55–57], we detected induction of free radicals and oxidative stress after
5-FU treatment of primary human cardiac cells. We also observed that cardiomyocytes were
more predisposed to enter autophagy as compared to endothelial cells. We previously reported
induction of mitochondrial autophagy in rat cardiomyocytes treated with 5-FU [62]. Several
publications have shown that autophagy is an escape mechanism that colon cancer cells per-
form during 5-FU treatment [63–65], and the interruption of the autophagic process enhances
tumor cell sensitivity to the drug. Autophagy is a conserved process that keeps a constant bal-
ance between biosynthetic and catabolic processes [66–68]. Although autophagy promotes a
cell-survival response, morphological features of autophagy have also been observed in dying
cells, although whether it is the cause of death or simply a stress response is controversial [69].
Autophagy, apoptosis and senescence can be induced by ROS elevation [70–72], and the ROS
scavenger NAC was able to revert induction of autophagic markers in cardiomyocytes. Taken
together with previous demonstrations of 5-FU smooth muscle cell alterations [39], these re-
sults indicate that 5-FU has substantial effects on the cardiovascular system. Further, the indi-
cation that the TP enzyme is up-regulated in atherosclerotic plaques [30] and during
myocardial damage [31], suggest that 5-FU and its prodrugs could directly damage the myo-
cardium, in particular in older cancer patients. In vivo studies using doses of 5-FU that inhib-
ited tumor growth are clearly associated with damage to renal endothelial cells, with TEM
analysis showing cytoplasmic vacuolization and membrane breakage, results in line with pre-
vous reports [73].
The absence of damage in heart tissues found in vivo could be explained by the relatively
young age of mice, which may not represent the aged cardiomyocytes in most oncologic pa-
tients. However, renal toxicity is a growing concern closely related to cardiovascular toxicity
[52,53].
The cardiotoxicity of fluoropyrimidines has been associated with induction of vasospasms
and subsequent angina/ischemia [74–77]. Direct endothelial damage could provoke thrombo-
sis and release of vasoactive substances [24] as has been observed in vivo [78] although there
are contrasting reports regarding the pro-thrombotic activity of 5-FU [79,80]. Cell cycle block,
apoptosis and alterations of contractility of smooth muscle cells treated with 5-FU in vitro have
recently been reported [39]. These data could explain the gastrointestinal side effects of 5-FU,
but they may also contribute to the enhanced vasoresponse associated with 5-FU induced angi-
na [12,21,81], in particular in the context of endothelial distress and senescence that we report
here. However, a lack of response of angina occurring during 5-FU treatment after vasodilator
calcium antagonist administration has been described [82], suggesting other mechanisms as
well. In addition, heart failure and myocardiotoxicity have also been reported as complications
of 5-FU therapy [12,19–21,82–84]. Another proposed mechanism leading to ischemia is the
Figure 9. In vivo effect of 5-FU. The CT26 murine colon adenocarcinoma cell line was used to evaluate effect of 5-FU in vivo on BALB/c mice. Sensitivity to
5-FU was demonstrated both in vitro in MTT (A, inset) and in vivo (A, B). Both treatment schedules (1 mg/kg every day, 10 mg/kg every other day)
significantly reduced tumor growth (A) and weight upon sacrifice (B) as compared to control (PBS). Hematoxylin/eosin staining of renal and cardiac tissues
from PBS and 5-FU treated animals (C). Transmission electron microscopy of renal tissues showed alterations (cytoplasmic vacuolization, membrane
breakage) of endothelial cells (insets) in both treated groups with respect to controls (D). Cardiac tissues showed intact cardiomyocytes (nuclei indicated by
thick white arrows) and occasional minor alterations of endothelial nuclei (thin black arrows) at the 10 mg/kg dose.
doi:10.1371/journal.pone.0115686.g009
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5-FU-induced decrease in the oxygen binding capacity of erythrocytes [85], suggesting de-
creased oxygen transfer capacity or inhibition of eNOS activity by Capecitabine [86]. Previous
in vivo studies showed the reduction of antioxidant defense capacities [13].
Finally, we observed induction of senescence in both cell types upon exposure to 5-FU. Se-
nescence cells activate signaling pathways that lead to the production and release of cytokines,
chemokines and growth factors. Interestingly, senescent cells have been found to induce neigh-
boring cells to enter senescence [87], likely through gap junction communication. Considering
the advanced age of the majority of oncologic patients, latent age-compromised heart tissue
performance could be further decreased by 5-FU administration.
Our data add new insights into the possible mechanisms involved in at least some of the
manifestations of 5-FU cardiotoxicity, and suggest potential prevention strategies to reduce
these severe side effects of an otherwise very useful drug family for treatment of
numerous cancers.
Supporting Information
S1 Fig. Metabolism of Capecitabine and 5-FU. Capecitabine, an orally administered fluoro-
pyrimidine carbamate 5-FU prodrug, is converted into 5-FU through three sequential steps: it
is converted to 5'-deoxy-5-fluorocytidine (5'-DFCR) by carboxylesterase (CES) located in the
liver, followed by the conversion of 5'-DFCR to 5'-deoxy-5-fluorouridine (5'-DFUR) by cyti-
dine deaminase (CDA) in the liver and in solid tumors. Finally, in solid tumors 5'-DFUR is
converted to 5-FU by thymidine phosphorylase (TP). 5-FU is converted to 5-fluorourodeox-
yuridine (5-FUdR) by the action of thymidine phosphorylase (TP). 5-FUdR is then converted
by thymidine kinase (TK) to 5-fluorodeoxyuridine monophosphate (5-FdUMP). 5-FdUMP in-
hibits DNA synthesis by competing with deoxyuridine monophosphate (dUMP) for binding to
thymidylate synthase (TS). 5-FU inhibits RNA synthesis, processing and function through a
pathway that involves its metabolism by orotate phosphoribosyltransferase (OPRT) to 5-fluor-
ouridine monophosphate (5-FUMP) and subsequent conversion to 5-fluorouridine triphos-
phate (5-FUTP) via 5-fluorouridine diphosphate (5-FUDP). 5-FU is catabolized and
inactivated through sequential enzymatic steps initiated by dihydropyrimidine dehydrogenase
(DPD).
(TIFF)
S2 Fig. Cytostatic effects of 5-FU on cardiomyocytes and endothelial cells. RawMTT data
are shown indicating the difference in growth of the different cell lines. MTT data at 72 hours
were used to calculate the EC50 for each cell line, again differences in replication rates are visi-
ble. 5-FU concentrations are reported in μM on a Log(10) scale.
(TIFF)
S3 Fig. Effects of 5-FU on the cell cycle. PI-staining cumulative histograms of three indepen-
dent experiments are shown for 96 hours 5-FU treated (10 nM to 1 mM) cells (A). Differences
among groups were not statistically significant although evident. The base analogue BrdU was
added to HCMs and HUVECs after 84 hours of drug treatment (100 nM to 1 mM) (B). For
each dot plot, the bottom gate comprises total BrdU- cells (not proliferating, G1 and G2/M
phases), while in the upper quadrant BrdU+ cells are proliferating (S phase). Vincristine was
used as positive control to arrest proliferation in G2/M-phase.
(TIFF)
S4 Fig. Apoptosis detection after 5-FU treatment. Representative histograms showing in-
crease of Annexin-V+ in cardiomyocytes and endothelial cells in response to 5-FU concentra-
tions from 10 nM to 1 mM. Vincristine was used as positive control. The effects of different
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drug concentrations are represented in gray scale. Dotted line: isotype control. Bold black line:
vincristine positive control.
(TIFF)
Author Contributions
Conceived and designed the experiments: AA DMN CF AB. Performed the experiments: CF
DB AB EP GF KD. Analyzed the data: AA DMN CF EM AB FS EOB. Contributed reagents/
materials/analysis tools: AA DMN FS. Wrote the paper: AA DMN CF AB EM EOB.
References
1. Grem JL (1997) Mechanisms of Action and Modulation of Fluorouracil. Semin Radiat Oncol 7: 249–
259. PMID: 10717222
2. Casale F, Canaparo R, Serpe L, Muntoni E, Pepa CD, et al. (2004) Plasma concentrations of 5-
fluorouracil and its metabolites in colon cancer patients. Pharmacol Res 50: 173–179. PMID:
15177306
3. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, et al. (1998) Design of a novel oral fluoropyrimidine
carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrat-
ed in human liver and cancer tissue. Eur J Cancer 34: 1274–1281. PMID: 9849491
4. Walko CM, Lindley C (2005) Capecitabine: a review. Clin Ther 27: 23–44. PMID: 15763604
5. Ghoshal K, Jacob ST (1997) An alternative molecular mechanism of action of 5-fluorouracil, a potent
anticancer drug. Biochem Pharmacol 53: 1569–1575. PMID: 9264308
6. Fox SB, Moghaddam A, Westwood M, Turley H, Bicknell R, et al. (1995) Platelet-derived endothelial
cell growth factor/thymidine phosphorylase expression in normal tissues: an immunohistochemical
study. J Pathol 176: 183–190. PMID: 7636628
7. Tabata T, Katoh M, Tokudome S, HosakawaM, Chiba K, et al. (2004) Bioactivation of capecitabine in
human liver: involvement of the cytosolic enzyme on 5'-deoxy-5-fluorocytidine formation. Drug Metab
Dispos 32: 762–767. PMID: 15205393
8. Buchel B, Rhyn P, Schurch S, Buhr C, Amstutz U, et al. (2013) LC-MS/MSmethod for simultaneous
analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for
therapeutic drug monitoring and toxicity prediction in cancer patients. Biomed Chromatogr 27: 7–16.
doi: 10.1002/bmc.2741 PMID: 22454320
9. Fraile RJ, Baker LH, Buroker TR, Horwitz J, Vaitkevicius VK (1980) Pharmacokinetics of 5-fluorouracil
administered orally, by rapid intravenous and by slow infusion. Cancer Res 40: 2223–2228. PMID:
7388790
10. van Groeningen CJ, Pinedo HM, Heddes J, Kok RM, de Jong AP, et al. (1988) Pharmacokinetics of 5-
fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation
schedule. Cancer Res 48: 6956–6961. PMID: 3180104
11. Gressett SM, Stanford BL, Hardwicke F (2006) Management of hand-foot syndrome induced by capeci-
tabine. J Oncol Pharm Pract 12: 131–141. PMID: 17022868
12. Sorrentino MF, Kim J, Foderaro AE, Truesdell AG (2012) 5-fluorouracil induced cardiotoxicity: review of
the literature. Cardiol J 19: 453–458. PMID: 23042307
13. Durak I, Karaayvaz M, Kavutcu M, Cimen MY, KacmazM, et al. (2000) Reduced antioxidant defense
capacity in myocardial tissue from guinea pigs treated with 5-fluorouracil. J Toxicol Environ Health A
59: 585–589. PMID: 10777249
14. Tsibiribi P, Bui-Xuan C, Bui-Xuan B, Lombard-Bohas C, Duperret S, et al. (2006) Cardiac lesions in-
duced by 5-fluorouracil in the rabbit. Hum Exp Toxicol 25: 305–309. PMID: 16866187
15. Amstutz U, Farese S, Aebi S, Largiader CR (2008) Hypermethylation of the DPYD promoter region is
not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy. J Exp Clin Cancer Res
27: 54. doi: 10.1186/1756-9966-27-54 PMID: 18937829
16. Yeh ET, Bickford CL (2009) Cardiovascular complications of cancer therapy: incidence, pathogenesis,
diagnosis, and management. J Am Coll Cardiol 53: 2231–2247. doi: 10.1016/j.jacc.2009.02.050 PMID:
19520246
17. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, et al. (2010) Cardiotoxicity of anticancer
drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 102: 14–25.
doi: 10.1093/jnci/djp440 PMID: 20007921
5-Fluorouracil Effects on Endothelial Cells and Cardiomyocytes
PLOS ONE | DOI:10.1371/journal.pone.0115686 February 11, 2015 21 / 25
18. Ewer MS, Ewer SM (2010) Cardiotoxicity of anticancer treatments: what the cardiologist needs to
know. Nat Rev Cardiol 7: 564–575. doi: 10.1038/nrcardio.2010.121 PMID: 20842180
19. Molteni LP, Rampinelli I, Cergnul M, Scaglietti U, Paino AM, et al. (2010) Capecitabine in breast cancer:
the issue of cardiotoxicity during fluoropyrimidine treatment. Breast J 16 Suppl 1: S45–48. doi: 10.
1111/j.1524-4741.2010.01004.x PMID: 21050310
20. Polk A, Vaage-Nilsen M, Vistisen K, Nielsen DL (2013) Cardiotoxicity in cancer patients treated with 5-
fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors.
Cancer Treat Rev 39: 974–984. doi: 10.1016/j.ctrv.2013.03.005 PMID: 23582737
21. Polk A, Vistisen K, Vaage-Nilsen M, Nielsen DL (2014) A systematic review of the pathophysiology of
5-fluorouracil-induced cardiotoxicity. BMC Pharmacol Toxicol 15: 47. doi: 10.1186/2050-6511-15-47
PMID: 25186061
22. Meyer CC, Calis KA, Burke LB, Walawander CA, Grasela TH (1997) Symptomatic cardiotoxicity associ-
ated with 5-fluorouracil. Pharmacotherapy 17: 729–736. PMID: 9250550
23. Schober C, Papageorgiou E, Harstrick A, Bokemeyer C, Mugge A, et al. (1993) Cardiotoxicity of 5-fluo-
rouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer 72: 2242–2247.
PMID: 8374883
24. Becker K, Erckenbrecht JF, Haussinger D, Frieling T (1999) Cardiotoxicity of the antiproliferative com-
pound fluorouracil. Drugs 57: 475–484. PMID: 10235688
25. Jensen SA, Sorensen JB (2006) Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil
or capecitabine. Cancer Chemother Pharmacol 58: 487–493. PMID: 16418875
26. Saif MW, Shah MM, Shah AR (2009) Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin
Drug Saf 8: 191–202. doi: 10.1517/14740330902733961 PMID: 19309247
27. Muneoka K, Shirai Y, Yokoyama N, Wakai T, Hatakeyama K (2005) 5-Fluorouracil cardiotoxicity in-
duced by alpha-fluoro-beta-alanine. Int J Clin Oncol 10: 441–443. PMID: 16369751
28. Bronckaers A, Gago F, Balzarini J, Liekens S (2009) The dual role of thymidine phosphorylase in
cancer development and chemotherapy. Med Res Rev 29: 903–953. doi: 10.1002/med.20159 PMID:
19434693
29. Ishikawa F, Miyazono K, Hellman U, Drexler H, Wernstedt C, et al. (1989) Identification of angiogenic
activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 338:
557–562. PMID: 2467210
30. Ignatescu MC, Gharehbaghi-Schnell E, Hassan A, Rezaie-Majd S, Korschineck I, et al. (1999)
Expression of the angiogenic protein, platelet-derived endothelial cell growth factor, in coronary
atherosclerotic plaques: In vivo correlation of lesional microvessel density and constrictive vascular re-
modeling. Arterioscler Thromb Vasc Biol 19: 2340–2347. PMID: 10521362
31. Hemalatha T, Balachandran C, Manohar BM, NayeemM, Subramaniam S, et al. (2010) Myocardial
expression of PDECGF is associated with extracellular matrix remodeling in experimental myocardial
infarction in rats. Biochem Cell Biol 88: 491–503. doi: 10.1139/o09-165 PMID: 20555391
32. Force T, Krause DS, Van Etten RA (2007) Molecular mechanisms of cardiotoxicity of tyrosine kinase in-
hibition. Nat Rev Cancer 7: 332–344. PMID: 17457301
33. Piegari E, De Angelis A, Cappetta D, Russo R, Esposito G, et al. (2013) Doxorubicin induces senes-
cence and impairs function of human cardiac progenitor cells. Basic Res Cardiol 108: 334. doi: 10.
1007/s00395-013-0334-4 PMID: 23411815
34. Sereno M, Brunello A, Chiappori A, Barriuso J, Casado E, et al. (2008) Cardiac toxicity: old and new is-
sues in anti-cancer drugs. Clin Transl Oncol 10: 35–46. PMID: 18208791
35. Menna P, Salvatorelli E, Minotti G (2008) Cardiotoxicity of antitumor drugs. Chem Res Toxicol 21:
978–989. doi: 10.1021/tx800002r PMID: 18376852
36. Brower V (2013) Cardiotoxicity debated for anthracyclines and trastuzumab in breast cancer. J Natl
Cancer Inst 105: 835–836. doi: 10.1093/jnci/djt161 PMID: 23733910
37. Grover S, Leong DP, Chakrabarty A, Joerg L, Kotasek D, et al. (2013) Left and right ventricular effects
of anthracycline and trastuzumab chemotherapy: a prospective study using novel cardiac imaging and
biochemical markers. Int J Cardiol 168: 5465–5467. doi: 10.1016/j.ijcard.2013.07.246 PMID:
24090744
38. Cardinale D, Bacchiani G, Beggiato M, Colombo A, Cipolla CM (2013) Strategies to prevent and treat
cardiovascular risk in cancer patients. Semin Oncol 40: 186–198. doi: 10.1053/j.seminoncol.2013.01.
008 PMID: 23540744
39. Filgueiras MdC, Morrot A, Soares PM, Costa ML, Mermelstein C (2013) Effects of 5-fluorouracil in nu-
clear and cellular morphology, proliferation, cell cycle, apoptosis, cytoskeletal and caveolar distribution
in primary cultures of smooth muscle cells. PLoS One 8: e63177. doi: 10.1371/journal.pone.0063177
PMID: 23646193
5-Fluorouracil Effects on Endothelial Cells and Cardiomyocytes
PLOS ONE | DOI:10.1371/journal.pone.0115686 February 11, 2015 22 / 25
40. L'Ecuyer T, Horenstein MS, Thomas R, Vander Heide R (2001) Anthracycline-induced cardiac injury
using a cardiac cell line: potential for gene therapy studies. Mol Genet Metab 74: 370–379. PMID:
11708868
41. Vene R, Arena G, Poggi A, D'Arrigo C, Mormino M, et al. (2007) Novel cell death pathways induced by
N-(4-hydroxyphenyl)retinamide: therapeutic implications. Mol Cancer Ther 6: 286–298. PMID:
17237288
42. Schumacker PT (2006) Reactive oxygen species in cancer cells: live by the sword, die by the sword.
Cancer Cell 10: 175–176. PMID: 16959608
43. Zafarullah M, Li WQ, Sylvester J, Ahmad M (2003) Molecular mechanisms of N-acetylcysteine actions.
Cell Mol Life Sci 60: 6–20. PMID: 12613655
44. Erusalimsky JD (2009) Vascular endothelial senescence: frommechanisms to pathophysiology. J Appl
Physiol (1985) 106: 326–332.
45. Gates PE, Strain WD, Shore AC (2009) Human endothelial function and microvascular ageing. Exp
Physiol 94: 311–316. doi: 10.1113/expphysiol.2008.043349 PMID: 19042980
46. Sikora E, Bielak-Zmijewska A, Mosieniak G (2013) Cellular Senescence in Ageing, Age-Related
Disease and Longevity. Curr Vasc Pharmacol.
47. Bu X, Le C, Jia F, Guo X, Zhang L, et al. (2008) Synergistic effect of mTOR inhibitor rapamycin and
fluorouracil in inducing apoptosis and cell senescence in hepatocarcinoma cells. Cancer Biol Ther 7:
392–396. PMID: 18075305
48. Gewirtz DA, Holt SE, Elmore LW (2008) Accelerated senescence: an emerging role in tumor cell re-
sponse to chemotherapy and radiation. Biochem Pharmacol 76: 947–957. doi: 10.1016/j.bcp.2008.06.
024 PMID: 18657518
49. te Poele RH, Okorokov AL, Jardine L, Cummings J, Joel SP (2002) DNA damage is able to induce se-
nescence in tumor cells in vitro and in vivo. Cancer Res 62: 1876–1883. PMID: 11912168
50. Coleman PR, Chang G, Hutas G, GrimshawM, Vadas MA, et al. (2013) Age-associated stresses in-
duce an anti-inflammatory senescent phenotype in endothelial cells. Aging (Albany NY) 5: 913–924.
PMID: 24334613
51. Boisen L, Drasbek KR, Pedersen AS, Kristensen P (2010) Evaluation of endothelial cell culture as a
model system of vascular ageing. Exp Gerontol 45: 779–787. doi: 10.1016/j.exger.2010.06.003 PMID:
20600781
52. Albini A, Donatelli F, Focaccetti C, D'Elios MM, Noonan DM (2012) Renal dysfunction and increased
risk of cardiotoxicity with trastuzumab therapy: a new challenge in cardio-oncology. Intern Emerg Med
7: 399–401. PMID: 22941411
53. Russo G, Cioffi G, Di Lenarda A, Tuccia F, Bovelli D, et al. (2012) Role of renal function on the
development of cardiotoxicity associated with trastuzumab-based adjuvant chemotherapy for early
breast cancer. Intern Emerg Med 7: 439–446. PMID: 22714882
54. Albini A, Cesana E, Donatelli F, Cammarota R, Bucci EO, et al. (2011) Cardio-oncology in targeting the
HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors. Future Cardiol 7: 693–
704. doi: 10.2217/fca.11.54 PMID: 21929348
55. Eskandari MR, Moghaddam F, Shahraki J, Pourahmad J (2014) A comparison of cardiomyocyte cyto-
toxic mechanisms for 5-fluorouracil and its pro-drug capecitabine. Xenobiotica: 1–9. PMID: 25547628
56. Lamberti M, Porto S, Marra M, Zappavigna S, Grimaldi A, et al. (2012) 5-Fluorouracil induces apoptosis
in rat cardiocytes through intracellular oxidative stress. J Exp Clin Cancer Res 31: 60. doi: 10.1186/
1756-9966-31-60 PMID: 22812382
57. Lamberti M, Porto S, Zappavigna S, Addeo E, Marra M, et al. (2014) A mechanistic study on the cardio-
toxicity of 5-fluorouracil in vitro and clinical and occupational perspectives. Toxicol Lett 227: 151–156.
doi: 10.1016/j.toxlet.2014.03.018 PMID: 24704391
58. Cwikiel M, Eskilsson J, Albertsson M, Stavenow L (1996) The influence of 5-fluorouracil and methotrex-
ate on vascular endothelium. An experimental study using endothelial cells in the culture. Ann Oncol 7:
731–737. PMID: 8905032
59. Wada H, Nagano H, Yamamoto H, Noda T, Murakami M, et al. (2009) Combination of interferon-alpha
and 5-fluorouracil inhibits endothelial cell growth directly and by regulation of angiogenic factors re-
leased by tumor cells. BMCCancer 9: 361. doi: 10.1186/1471-2407-9-361 PMID: 19821965
60. Ijichi K, Adachi M, Ogawa T, Hasegawa Y, Murakami S (2014) Cell-cycle distribution and Thymidilate
Synthatase (TS) expression correlate with 5-FU resistance in head and neck carcinoma cells. Antican-
cer Res 34: 2907–2911. PMID: 24922653
61. Tokalov SV, Abolmaali ND (2010) Protection of p53 wild type cells from taxol by nutlin-3 in the com-
bined lung cancer treatment. BMCCancer 10: 57. doi: 10.1186/1471-2407-10-57 PMID: 20178585
5-Fluorouracil Effects on Endothelial Cells and Cardiomyocytes
PLOS ONE | DOI:10.1371/journal.pone.0115686 February 11, 2015 23 / 25
62. Albini A, Donatelli F, Sessa F, Noonan DM, Tosetti F (2011) Response: Re: Neurocognitive Functioning
in Adult Survivors of Childhood Noncentral Nervous System Cancers. J Natl Cancer Inst 103: 608–
609. doi: 10.1093/jncimonographs/lgr031 PMID: 22043053
63. Bijnsdorp IV, Peters GJ, Temmink OH, FukushimaM, Kruyt FA (2010) Differential activation of cell
death and autophagy results in an increased cytotoxic potential for trifluorothymidine compared to 5-
fluorouracil in colon cancer cells. Int J Cancer 126: 2457–2468. doi: 10.1002/ijc.24943 PMID:
19816940
64. Li J, Hou N, Faried A, Tsutsumi S, Kuwano H (2010) Inhibition of autophagy augments 5-fluorouracil
chemotherapy in human colon cancer in vitro and in vivo model. Eur J Cancer 46: 1900–1909. doi: 10.
1016/j.ejca.2010.02.021 PMID: 20231086
65. Li J, Hou N, Faried A, Tsutsumi S, Takeuchi T, et al. (2009) Inhibition of autophagy by 3-MA enhances
the effect of 5-FU-induced apoptosis in colon cancer cells. Ann Surg Oncol 16: 761–771. doi: 10.1245/
s10434-008-0260-0 PMID: 19116755
66. Gozuacik D, Kimchi A (2004) Autophagy as a cell death and tumor suppressor mechanism. Oncogene
23: 2891–2906. PMID: 15077152
67. Levine B, Klionsky DJ (2004) Development by self-digestion: molecular mechanisms and biological
functions of autophagy. Dev Cell 6: 463–477. PMID: 15068787
68. Yousefi S, Perozzo R, Schmid I, Ziemiecki A, Schaffner T, et al. (2006) Calpain-mediated cleavage of
Atg5 switches autophagy to apoptosis. Nat Cell Biol 8: 1124–1132. PMID: 16998475
69. Shimizu S, Kanaseki T, Mizushima N, Mizuta T, Arakawa-Kobayashi S, et al. (2004) Role of Bcl-2 fami-
ly proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat Cell Biol 6:
1221–1228. PMID: 15558033
70. Alili L, Diekmann J, Giesen M, Holtkotter O, Brenneisen P (2014) A drug-induced accelerated senes-
cence (DIAS) is a possibility to study aging in time lapse. Age (Dordr).
71. Dai DF, Chiao YA, Marcinek DJ, Szeto HH, Rabinovitch PS (2014) Mitochondrial oxidative stress in
aging and healthspan. Longev Healthspan 3: 6. doi: 10.1186/2046-2395-3-6 PMID: 24860647
72. Gemma C, Vila J, Bachstetter A, Bickford PC (2007) Oxidative Stress and the Aging Brain: From Theo-
ry to Prevention.
73. Metz-Kurschel U, Kurschel E, Wagner K, Aulbert E, Graben N, et al. (1990) Folate nephropathy occur-
ring during cytotoxic chemotherapy with high-dose folinic acid and 5-fluorouracil. Ren Fail 12: 93–97.
PMID: 2236732
74. Kosmas C, Kallistratos MS, Kopterides P, Syrios J, Skopelitis H, et al. (2008) Cardiotoxicity of fluoropyr-
imidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 134:
75–82. PMID: 17636329
75. Kleiman NS, Lehane DE, Geyer CE Jr., Pratt CM, Young JB (1987) Prinzmetal's angina during 5-fluoro-
uracil chemotherapy. Am J Med 82: 566–568. PMID: 3826112
76. Maseri A, Lanza G (2001) Fluorouracil-induced coronary artery spasm. Am J Med 111: 326–327.
PMID: 11566467
77. Weidmann B, Teipel A, Niederle N (1994) The syndrome of 5-fluorouracil cardiotoxicity: an elusive car-
diopathy. Cancer 73: 2001–2002. PMID: 8137229
78. Cwikiel M, Zhang B, Eskilsson J, Wieslander JB, Albertsson M (1995) The influence of 5-fluorouracil on
the endothelium in small arteries. An electron microscopic study in rabbits. Scanning Microsc 9: 561–
576. PMID: 8714749
79. Cwikiel M, Persson SU, Larsson H, Albertsson M, Eskilsson J (1995) Changes of blood viscosity in pa-
tients treated with 5-fluorouracil—a link to cardiotoxicity? Acta Oncol 34: 83–85. PMID: 7873217
80. Swystun LL, Shin LY, Beaudin S, Liaw PC (2009) Chemotherapeutic agents doxorubicin and epirubicin
induce a procoagulant phenotype on endothelial cells and blood monocytes. J Thromb Haemost 7:
619–626. doi: 10.1111/j.1538-7836.2009.03300.x PMID: 19187077
81. Mosseri M, Fingert HJ, Varticovski L, Chokshi S, Isner JM (1993) In vitro evidence that myocardial is-
chemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstric-
tion of vascular smooth muscle. Cancer Res 53: 3028–3033. PMID: 8391384
82. Tsibiribi P, Descotes J, Lombard-Bohas C, Barel C, Bui-Xuan B, et al. (2006) Cardiotoxicity of 5-fluoro-
uracil in 1350 patients with no prior history of heart disease. Bull Cancer 93: E27–30. PMID: 16567310
83. Coronel B, Madonna O, Mercatello A, Caillette A, Moskovtchenko JF (1988) Myocardiotoxicity of 5 fluo-
rouracil. Intensive Care Med 14: 429–430. PMID: 3403776
84. Misset B, Escudier B, Leclercq B, Rivara D, Rougier P, et al. (1990) Acute myocardiotoxicity during 5-
fluorouracil therapy. Intensive Care Med 16: 210–211. PMID: 2351781
5-Fluorouracil Effects on Endothelial Cells and Cardiomyocytes
PLOS ONE | DOI:10.1371/journal.pone.0115686 February 11, 2015 24 / 25
85. Spasojevic I, Jelic S, Zakrzewska J, Bacic G (2009) Decreased oxygen transfer capacity of erythro-
cytes as a cause of 5-fluorouracil related ischemia. Molecules 14: 53–67.
86. Gajalakshmi P, Priya MK, Pradeep T, Behera J, Muthumani K, et al. (2013) Breast cancer drugs damp-
en vascular functions by interfering with nitric oxide signaling in endothelium. Toxicol Appl Pharmacol
269: 121–131. doi: 10.1016/j.taap.2013.03.011 PMID: 23531514
87. Nelson G, Wordsworth J, Wang C, Jurk D, Lawless C, et al. (2012) A senescent cell bystander effect:
senescence-induced senescence. Aging Cell 11: 345–349. doi: 10.1111/j.1474-9726.2012.00795.x
PMID: 22321662
5-Fluorouracil Effects on Endothelial Cells and Cardiomyocytes
PLOS ONE | DOI:10.1371/journal.pone.0115686 February 11, 2015 25 / 25
